Rocket Pharmaceuticals
Logotype for Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals (RCKT) investor relations material

Rocket Pharmaceuticals Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Rocket Pharmaceuticals Inc
Q3 2026 earnings summary12 Nov, 2026

Executive summary

  • Q3 2026 net loss narrowed to $49.2M from $50.3M; nine-month net income of $26.4M included a one-time $178.2M gain from the PRV sale.

  • Priorities included advancing Danon and cardiovascular gene therapy programs and preparing KRESLADI for launch; commercial readiness was achieved October 1, with two treatment centers ready for onboarding.

Financial highlights

  • Q3 operating expenses were $51.0M versus $52.2M a year earlier; R&D was $31.2M versus $34.1M and G&A was $19.8M versus $18.4M.

  • Nine-month operating expenses fell $41.4M year over year to $146.4M; R&D declined $20.5M to $92.1M and G&A declined $17.5M to $54.3M.

  • Q3 basic and diluted loss per share were $0.43 versus $0.45; nine-month diluted EPS was $0.23 versus a $1.63 loss.

  • September 30 cash, cash equivalents and investments totaled $279.4M, versus $188.9M at December 31, 2025; total assets were $419.5M and long-term debt was $30.4M.

  • Excluding the PRV-sale gain, operating activities used $124.1M cash in the first nine months; financing provided $34.2M and investing activities provided $107.8M.

Outlook and guidance

  • Current operating plan and available cash, investments, PRV proceeds and initial debt draw are expected to fund operations into Q3 2028; conditional additional borrowing could extend runway into 2029.

  • RP-A501 pivotal-study dosing is expected to finish by mid-2027, with topline 12-month results anticipated in mid-2028.

  • R&D spending is expected to remain significant and may rise as programs advance; KRESLADI is not expected to generate material near-term revenue given its ultra-rare population and phased rollout.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Rocket Pharmaceuticals earnings date

Logotype for Rocket Pharmaceuticals Inc
Q4 202626 Feb, 2027
Rocket Pharmaceuticals
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Rocket Pharmaceuticals earnings date

Logotype for Rocket Pharmaceuticals Inc
Q4 202626 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Rocket Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare and life-threatening genetic diseases. The company’s pipeline includes gene therapy programs targeting both hematologic and cardiovascular disorders. Rocket Pharmaceuticals uses lentiviral and adeno-associated virus (AAV) vectors to deliver corrective genes to patients' cells, aiming to provide long-term, potentially curative treatments. Its therapies are designed to address the underlying genetic causes of diseases, with a focus on disorders with limited treatment options. The company is headquartered in Cranbury, New Jersey, and its shares are listed on the NASDAQ.